About us
- >
- About us >
- Information >
- Announcement
Announcement
-
2022-10-18The Phase III clinical trial of ENERGI-F703 diabetic foot ulcer topical gel, which was applied for in the US, has successfully completed the 30-day re
-
2022-09-19Applied to the US FDA for an Investigational New Drug (IND) application for the Phase III clinical trial of ENERGI-F703 diabetic foot ulcer topical ge
-
2022-07-25Energenesis Biomedical has obtained US patent for developing AMPK activation technology for the treatment of human inflammatory diseases.
-
2022-07-11The clinical Phase II trial results of our company's novel diabetic foot ulcer healing drug (ENERGI-F703 GEL) have been published in the internat
-
2022-03-01"Compound for Activating AMPK and Its Use" has been approved for a Malaysian invention patent.
-
2022-02-10Energenesis Biomedical has obtained a US patent for the invention that promotes wound healing.
-
2021-07-02Energenesis Biomedical Announces Positive End-of-Phase 2 Meeting with FDA on ENERGI-F703 for the Treatment of Diabetic Foot Ulcers
-
2021-04-19The Japan patent “Compound for Activating AMPK and Used Thereof” is granted.
-
2021-02-18The Korean patent “Compound for Activating AMPK and Used Thereof” is granted.
-
2020-12-11The Canada patent “Compound for Activating AMPK and Used Thereof” is granted.